MedPath

Nutrition and Cancer Outcomes in Shaanxi Chemoradiotherapy

Recruiting
Conditions
Chemoradiotherapy
Cancer
Nutrition, Healthy
Oncology
Clinical Outcomes
Registration Number
NCT06219083
Lead Sponsor
Xiaoqin Luo
Brief Summary

The study investigates the impact of nutritional status on the clinical outcomes of cancer patients in Shaanxi Province undergoing chemoradiotherapy. It focuses on understanding how diet and nutrition affect the effectiveness and side effects of cancer treatments.

Detailed Description

Study Purpose and Content: The research aims to investigate the nutritional status and trends in cancer patients at different stages of chemoradiotherapy in Shaanxi Province.

Registry Procedures: The study will recruit patients from 20 hospitals across the province, tracking their nutritional status, disease condition, and quality of life through various stages of treatment.

Quality Control: Nutritional assessments are to be conducted at specific intervals, and all research staff are required to undergo training for consistency in data collection and patient evaluation.

Ethical Considerations: The study ensures informed consent from participants and confidentiality of personal information, with approval from the ethics committee of Xi'an Jiaotong University Medical College.

Data Collection and Analysis: Data will be gathered through detailed patient surveys, laboratory tests, and physical measurements, with subsequent analysis to establish a predictive model for cancer patient survival based on nutritional indicators.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
10000
Inclusion Criteria
  • Adults aged 18 years and above
  • Pathologically diagnosed with malignant tumors
  • Scheduled to undergo radiotherapy and/or chemotherapy
  • Clear consciousness, no communication barriers
  • Willing to undergo follow-up, not in a near-death condition
Exclusion Criteria
  • Patients without a pathological diagnosis of malignant tumors
  • Patients with AIDS
  • Patients with mental or cognitive disorders
  • Patients who have undergone organ transplantation
  • Patients with a life expectancy less than 12 months
  • Pregnant women
  • Patients currently participating in other clinical intervention studies

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
BMIthrough study completion, an average of 1 year

BMI was kept at 1 decimal place.

Heightthrough study completion, an average of 1 year

The accuracy of the height was 0.5cm, and this value should be noted if there was ascites, systemic edema, and huge tumors.

Weightthrough study completion, an average of 1 year

Weight accuracy to 0.2kg,and this value should be noted if there was ascites, systemic edema, and huge tumors.

Secondary Outcome Measures
NameTimeMethod
Total Cholesterol1 year

mmol/L

Albumin1 year

g/L

Interleukin-1 (IL-1)1 year

Ug

Creatinine1 year

mmol/L

Platelets1 year

\*10\^9/L

Chemotherapy toxic effects6 months

the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0)

Prealbumin1 year

mg/L

Urea Nitrogen1 year

mmol/L

Triglycerides1 year

mmol/L

Interleukin-6 (IL-6)1 year

Ug

Total Protein1 year

g/L

Glucose1 year

mmol/L

Low-Density Lipoprotein (LDL) Cholesterol1 year

mmol/L

Hemoglobin1 year

\*10\^9/L

Transferrin1 year

g/L

C-reactive Protein1 year

mg/L

Aspartate Aminotransferase (AST)1 year

U/L

Alanine Aminotransferase (ALT)1 year

U/L

Tumor Necrosis Factor-alpha (TNF-α)1 year

nmol/l

Total Bilirubin1 year

umol/L

Direct Bilirubin1 year

umol/L

Neutrophil Count1 year

\*10\^9/L

Lymphocyte Count1 year

\*10\^9/L

High-Density Lipoprotein (HDL) Cholesterol1 year

mmol/L

Leukocytes (White Blood Cells)1 year

\*10\^9/L

Red Blood Cells1 year

\*10\^12/L

Trial Locations

Locations (1)

Xi 'an Jiaotong University

🇨🇳

Xi'an, Shaanxi, China

© Copyright 2025. All Rights Reserved by MedPath